Merck & Co., Inc. (MRK) Supplier List — 6 Verified Relationships
Merck & Co., Inc.'s supply chain includes active pharmaceutical ingredient (API) suppliers, contract manufacturers, logistics partners, and clinical research organizations named in annual and quarterly filings.
Merck & Co., Inc. Suppliers (6 relationships from SEC filings)
The following suppliers are named in Merck & Co., Inc.'s SEC regulatory filings. Each entry includes the relationship type, confidence score based on filing evidence, and a direct excerpt from the source filing. Confidence scores reflect the directness of the disclosure — "High" indicates the company is named explicitly as a supplier in the filing text.
| Ticker | Company | Relationship | Confidence | Filing Evidence |
|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | Spend | High | Reblozyl is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol Myers Squibb Company (BMS) |
| CIDARA | Cidara | Spend | High | Merck acquired Cidara, a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, for $ 9.2 billion |
| DAIICHI-SANKYO | Daiichi Sankyo | Spend | High | Merck is working with Daiichi Sankyo to address FDA feedback |
| J-J-INNOVATIVE-MEDICINE | J&J Innovative Medicine | Spend | High | Under a previous license agreement between Cidara and J&J Innovative Medicine...J&J Innovative Medicine is eligible to receive up to $ 105 million in regulatory milestones and up to $ 455 million in sales-based… |
| VERONA-PHARMA | Verona Pharma | Spend | Medium | Animal health sales growth was due to the performance of both livestock and companion animal products. (which was obtained as part of the October 2025 acquisition of Verona Pharma plc [Verona Pharma]). |
| ORANY | ORANGE | Spend | Medium | agencies and managed health care providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccines are sold primarily to physicians, wholesalers, distributors… |
Filing Evidence Highlights
These excerpts are taken directly from Merck & Co., Inc.'s SEC filings and cross-referenced against counterparty disclosures. Every relationship in ChainSifter traces back to a primary regulatory source.
"Reblozyl is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol Myers Squibb Company (BMS)"
— Merck & Co., Inc. SEC filing, sourced via ChainSifter
"Merck acquired Cidara, a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, for $ 9.2 billion"
— Merck & Co., Inc. SEC filing, sourced via ChainSifter
"Under a previous license agreement between Cidara and J&J Innovative Medicine...J&J Innovative Medicine is eligible to receive up to $ 105 million in regulatory milestones and up to $ 455 million in sales-based milestones related to MK-1406."
— Merck & Co., Inc. SEC filing, sourced via ChainSifter
Merck & Co., Inc. Key Customers (1 mapped)
The following organizations are disclosed as significant customers of Merck & Co., Inc. in SEC filings. Customer relationships are captured when a counterparty accounts for a material portion of revenue or is otherwise named as a significant buyer in 10-K or 10-Q disclosures.
| Ticker | Company | Relationship | Confidence | Filing Evidence |
|---|---|---|---|---|
| THIRD-PARTY | third party | Spend | Medium | The Company is working to reduce its Scope 3 emissions through a robust supplier engagement approach to drive collaboration upstream and downstream in its value chain |
About This Data
ChainSifter extracts supply chain relationships from public SEC regulatory filings — 10-K annual reports, 10-Q quarterly reports, and 8-K current reports filed with the SEC. The extraction pipeline identifies named suppliers, contract manufacturers, key customers, and distribution partners, then cross-references each disclosure against the counterparty's own filings to validate and strengthen confidence scores.
For Merck & Co., Inc., the 6 supplier relationships reflect disclosures spanning multiple filing years. Newer filings carry higher weight; discontinued relationships are flagged and removed from the active graph. The data does not represent Merck & Co., Inc.'s complete supplier universe — only relationships explicitly named in public filings are captured.
For the full interactive graph including risk scores, relationship timelines, and filing links, see the MRK supply chain page.
Get alerts when Merck & Co., Inc.'s supply chain changes
ChainSifter monitors new SEC filings and notifies you when MRK's supplier or customer relationships change — new vendors added, existing ones dropped, or concentration risks flagged.
View MRK Chain Page See PricingFrequently Asked Questions
How many suppliers does Merck & Co., Inc. have?
ChainSifter has mapped 6 verified supplier relationships for MRK based on disclosures in SEC 10-K and 10-Q filings. The actual number of suppliers in Merck & Co., Inc.'s full supply chain is larger — these are the relationships explicitly named in regulatory filings.
Where does Merck & Co., Inc. source its key components?
Based on SEC filing disclosures, Merck & Co., Inc. sources from a combination of domestic and international suppliers. The specific vendors and relationship details are visible on the full MRK chain page.
How is ChainSifter's supply chain data verified?
Every relationship in ChainSifter is extracted from primary SEC regulatory filings — 10-K annual reports and 10-Q quarterly reports — filed by public companies. Each entry links to the source filing text. Data is cross-referenced across both the reporting company's filings and the counterparty's own disclosures.
Can I get alerts when Merck & Co., Inc.'s supply chain changes?
Yes. ChainSifter monitors new SEC filings and triggers alerts when new supplier or customer relationships are added or removed. Create a free account and set up alerts for MRK on the MRK chain page.
What is Merck & Co., Inc.'s supply chain risk profile?
Merck & Co., Inc.'s supply chain risk is assessed based on supplier concentration, geographic exposure, and disclosed dependencies in regulatory filings. View the risk score and detailed breakdown on the MRK supply chain page.
Related Supply Chain Pages
ChainSifter covers pharmaceuticals supply chain relationships across thousands of public companies. Explore related chains:
ChainSifter provides supply chain relationship data derived from public SEC regulatory filings for research and informational purposes only. This is not investment advice. Relationship data is sourced exclusively from publicly available company disclosures. Data accuracy depends on the quality and completeness of underlying filings. Last generated: 2026-09-25. See full disclaimer.